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Abstract
Background: In the past few decades, much has been learned about the pathophysiology of restless legs syndrome (RLS). Investigators have studied
neuropathology, imaging, electrophysiology, and genetics of RLS, identifying brain regions and biological systems affected in RLS. This manuscript will review RLS
pathophysiology literature, examining the RLS state through consideration of the neuroanatomy, then the biological, organ, and genetic systems.
Methods: Pubmed (1966 to April 2016) was searched for the term ‘‘restless legs syndrome’’ cross-referenced with ‘‘pathophysiology,’’ ‘‘pathogenesis,’’
‘‘pathology,’’ or ‘‘imaging.’’ English language papers were reviewed. Studies that focused on RLS in relation to another disease were not reviewed.
Results: Although there are no gross structural brain abnormalities in RLS, widespread brain areas are activated, including the pre- and post-central gyri,
cingulate cortex, thalamus, and cerebellum. Pathologically, the most consistent finding is striatal iron deficiency in RLS patients. A host of other biological systems
are also altered in RLS, including the dopaminergic, oxygen-sensing, opioid, glutamatergic, and serotonergic systems. Polymorphisms in genes including BTBD9
and MEIS1 are associated with RLS.
Discussion: RLS is a neurologic sensorimotor disorder that involves pathology, most notably iron deficiency, in motor and sensory brain areas. Brain areas not
subserving movement or sensation such as the cingulate cortex and cerebellum are also involved. Other biological systems including the dopaminergic, oxygen-
sensing, opioid, glutamatergic, and serotonergic systems are involved. Further research is needed to determine which of these anatomic locations or biological
systems are affected primarily, and which are affected in a secondary response.
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Introduction
Restless legs syndrome (RLS) is one of the most common neurologic
diseases, affecting up to 10% of adults in industrialized nations.1–3
Clinically significant RLS is estimated to affect 2–3% of adults.4 RLS is
a multifaceted neuropsychological disease that consists of abnormal-
ities in sensation, motor activity, arousal, and psychology. More
specifically, RLS consists of an inescapable urge to move, often
accompanied by sensory discomfort. Other features required for a
diagnosis of RLS include worsening of symptoms at night, with
inactivity, and development of relief with movement. As a result of
these symptoms, sleep is markedly disturbed,5,6 and depression is
common.7–9 Still other identifying psychological features of RLS
include impulsivity and problems with decision-making.10 This broad
description of RLS, although phenomenological, serves to guide a
neuroanatomical approach when considering RLS pathophysiology.
Neuroanatomic regions likely involved in RLS are those associated
with abnormal movement, sensation, arousal, and psychology, and
include cortical and spinal areas, multimodal thalamic nuclei,
extrapyramidal motor centers, limbic cortices, and integrative
cerebellar centers. This anatomical approach is especially pertinent
as the biological mechanisms underlying RLS are poorly understood.
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Nevertheless, when considering RLS pathophysiology, it is impera-
tive to review biological systems that have been implicated and studied
in relation to RLS. These systems occur at the ligand and elemental
level, including the dopaminergic and iron systems; at the organ level,
including the peripheral arterial and nervous systems; and at the
molecular and genetic level, including the oxygen sensing and genetic
pathways. This review of RLS pathophysiology will examine the RLS
state through consideration of the disease starting with a reflection of
the involved neuroanatomy, then attending to the biological, organ,
and genetic systems. It will then end with discussion of where
pathophysiologic research has been deficient, and propose a direction
for future research to aid in uncovering the underlying mechanisms of
this common sleep disorder.
Methods
The authors used PubMed (1966 to April 2016) to search for the
term ‘‘restless legs syndrome’’ cross-referenced with ‘‘pathophysiol-
ogy,’’ ‘‘pathogenesis,’’ ‘‘pathology,’’ or ‘‘imaging.’’ English language
papers were reviewed. Also reviewed were pertinent papers from the
reference list of the above-matched manuscripts. Studies that focused
on RLS in relation to another disease such as Parkinson’s disease,
multiple sclerosis, or renal failure were not reviewed.
Results
The pathophysiology of RLS will be reviewed in the following
sections, first using a neuroanatomical approach, followed by a
consideration of the different biological systems involved in RLS
patients.
Consideration of neuroanatomy as it relates to RLS
Early magnetic resonance imaging (MRI) studies did not reveal
gross structural brain abnormality in RLS.11 Rather, MRI measure-
ment of brain iron demonstrated a deficiency of iron in the substantia
nigra, putamen, caudate nucleus, and thalamus.12–14 This brain iron
deficiency was confirmed by direct neuropathologic demonstration of
low levels of iron, ferritin, and transferrin in the substantia nigra of
RLS patients.15,16 Although early studies focused on structures of the
basal ganglia, development of functional imaging has allowed an
agnostic approach, shifting attention to areas not previously implicated
in RLS. During periods when RLS patients were actively experiencing
symptoms, functional MRI (fMRI) showed activation of the cerebel-
lum and contralateral thalamus.17 More recent fMRI studies of
persons with active RLS symptoms demonstrated activation in these
and other areas, including the midbrain, dorsolateral prefrontal cortex,
anterior cingulate cortex, left precentral gyrus, posterior central gyrus,
pars opercularis, and putamen.18 The numerous regions activated in
RLS reflect the complexity of this neuropsychiatric disease. Table 1
lists different brain regions that have been studied in RLS and what
these studies have found referable to these areas. The paragraphs
below outline these findings.
Neuroanatomy of motion and sensation. On the most basic level, RLS
consists of sensory discomfort and an urge to move, which drives
movement. So it is no surprise that areas involved in sensation and
movement, including the post- and pre-central gyri, are activated
when RLS symptoms are present. Also activated in RLS are
extrapyramidal subcortical structures, including putamen.18,19
Functional imaging in RLS has not shown increased activity in
substantia nigra; however, several T2 relaxometry studies have
demonstrated reduced iron in substantia nigra of persons with
RLS.12,20–22 Striatum has been more extensively studied using
single-photon emission computed tomography, which has yielded
conflicting results with increased, decreased, and even normal striatal
dopamine binding (detailed in the section on dopamine ).23–26
Many studies have focused on the thalamus in RLS,17,19,42 and as a
brain region subserving sensation this seems fitting. In several fMRI
studies in RLS patients, there is increased activity reported in the
thalamus.17–19,42,43 One voxel-based morphometry MRI study
demonstrated an increase in gray matter density in the thalamic
pulvinar nuclei in RLS compared with controls, suggesting a chronic
increase in afferent input, but other similar MRI studies have not
replicated this finding.18,29,39 Proton magnetic resonance spectroscopy
has demonstrated heightened glutamatergic activity but normal
N-acetylaspartate levels in the thalamus of persons with RLS,40,43
suggesting that neurons are intact in the thalamus but hyperactive in
RLS. Glutamate is abundant in the thalamus, and is required for
communication between the thalamus and the cortex.44,45
When considering the available data regarding motor and sensory
areas, there is consistency in that there is widespread activation of
neuroanatomical areas, including the somatosensory cortex, thalamus,
and parts of the striatum.18,19 There is also consensus from
neuropathologic and imaging studies that there is a relative deficiency
of iron in extrapyramidal motor regions.15,20–22 There is less consensus
on the involvement and/or role of sensory structures, most notably the
thalamus, in the pathophysiology of RLS, although there is likely to be
increased activation. Lastly, although conventional imaging has not
revealed any structural abnormality in motor structures, some but not
all voxel-based morphometry studies have revealed increased gray
matter density in sensory and motor structures.18,29,31,39 Differences in
findings across studies may be related to genetic or population
differences (Asian versus Western European), variation in RLS
phenotype (early versus late onset), medication exposure status, and
differences in imaging analysis techniques.
Neuroanatomy of arousal. In RLS, uncomfortable sensorimotor
symptoms alert the sufferer even in the face of sleepiness. When
RLS symptoms are present, fMRI has shown activation in the
midbrain and pons, and throughout different cortical areas, including
the primary motor cortex, somatosensory cortex, and anterior
cingulate cortex, the inferior, and superior parietal lobules, and the
dorsolateral prefrontal cortex.18,19 Activation of brainstem arousal
systems in the dorsal midbrain and pons would result in alertness and
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excitation of cortical areas. In turn, widespread cortical activation may
relate to increased arousal and an inability to sleep.
Bucher and colleagues17 in a fMRI study of persons experiencing
sensory RLS symptoms showed bilateral activation of the cerebellum
and contralateral activation of the thalamus. In the same study, when
sensory RLS symptoms co-occurred with periodic limb movements
during sleep (PLMS), there was additional activation in the red nuclei
and brainstem close to the reticular formation. PLMS are often
associated with cortical arousal, previously thought to occur as a
consequence of movement. We now know that arousal can either
precede or follow PLMS, suggesting that they occur as a complex
rather than one being the consequence of the other.46
Neuroanatomy of emotion. Although the core sensorimotor symptoms
of RLS are most conspicuous, there are non-sensorimotor features of
RLS that extend its phenomenology, including a tendency toward
depression, impulsivity, and PLMS.
Functional imaging in RLS demonstrates activation of brain regions
associated with emotion, including the anterior and posterior cingulate
gyri and dorsolateral prefrontal cortex.18,19 Voxel-based morphometry
MRI shows a decrease in gray matter density in the medial frontal and
parietal lobes in persons with RLS,27 whereas a German study showed
an increase in gray matter density in the hippocampus and medial
frontal lobe.28 However, additional voxel-based morphometry MRI
studies showed no difference in the anterior cingulate gray matter
density or in the whole brain gray matter compartments.18,32,34 In
addition, pathologic study and voxel-based morphometry MRI have
demonstrated that there is decreased white matter volume in the
corpus callosum and anterior cingulate gyrus in RLS, specifically
decreased in myelin integral proteins and myelin basic protein.33
Indeed, there is a well-known association between RLS and
depression.47 Lifetime prevalence of depression ranges between 19%
and 35% in persons with RLS, representing a greater than twofold
increased odds of depression compared with those without RLS.48–50
Another potential clinical correlate of altered limbic and behavioral
neuroanatomy is the increased impulsivity shown in persons with RLS,
who are more likely than controls without RLS to make risky choices
in studies using validated gambling task testing.10
Table 1. Brain Regions Implicated in Restless Legs Syndrome
Brain Region Abnormality
Prefrontal cortex q activity (fMRI),18 Q gray matter density (voxel morphometry MRI)27
Medial frontal q gray matter density28; « gray matter density (voxel morphometry MRI)29
Precentral gyrus q activity (fMRI),18 Q intra-cortical inhibition (TMS)30; q gray matter (voxel morphometry
MRI)31
Postcentral gyrus q activity (fMRI)18; q gray matter (voxel morphometry MRI)31
Anterior cingulate
cortex





Whole brain « gray matter (voxel morphometry MRI)18,34
Putamen Q iron staining (pathology),15,16,35Q iron (MRI),12Q dopamine-2 binding (PET),36Q dopamine-2
receptor levels (pathology)37
Substantia nigra Q iron (pathology),15,16,35 Q iron (MRI),12,13 Q iron (phase imaging),22 q tyrosine hydroxylase
levels (pathology)37
Caudate Q iron staining (pathology), Q iron (MRI)14
Pons, medulla « Serotonin transporter38
Thalamus q activity (fMRI),17,18 q gray matter density pulvinar (Voxel morphometry MRI),39 « NAA,40
q glutamate (MRS),40 Q b-endorphin positive cells (pathology),41 Q iron (MRI)14
Cerebellum q activity (fMRI),17,18 Q gray matter density (voxel morphometry MRI)27
Abbreviations: q, Increased; Q, Decreased; «, Unchanged; fMRI, Functional Magnetic Resonance Imaging; MRS, Magnetic Resonance Spectroscopy;
NAA, N-acetylaspartate; PET, Positron Emission Tomography; TMS, Transcranial Magnetic Stimulation.
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Neuroanatomy of periodic limb movements during sleep. Although
not a diagnostic criterion of RLS, PLMS are commonly associated
with RLS and may provide insight into its pathophysiology.6
Movements are stereotypic, occur during sleep, and consist of brisk,
brief (0.5–5 second) movements of the feet and lower more than upper
legs (Figure 1). By definition, PLMS occur in a chain of four or more
movements with an inter-movement interval between 5 and 90
seconds. PLMS may number into the hundreds across a night’s sleep.
The anatomic generator of these movements is suggested by the
pattern of muscular recruitment, which tends to be uniform up or
down spinal segments (L3 to S1), suggesting spinal cord hyperexcit-
ability.51 Electrophysiologic study of persons with RLS corroborates
spinal cord hyperexcitability, showing a lower threshold and greater
spatial spread of the spinal cord flexor response (by medial plantar
nerve stimulation).52 That PLMS involve spinal cord hyperexcitability
is not surprising, as the movement itself resembles either an extensor
plantar response or triple flexion. It is also possible that PLMS arise
further upstream in the brainstem. One functional imaging study
demonstrated activation in the brainstem near the reticular formation,
when both RLS sensorimotor symptoms and PLMS co-occurred.17
Other neuroimaging techniques. PLMS are one associated phenomenon
that suggest that there is central nervous system hyperexcitability in RLS.
Other supporting evidence includes disinhibition of auditory startle in the
RLS patients, suggesting activation of reticulospinal pathways from
dysfunction in the diencephalon or above.53 Transcranial magnetic
stimulation (TMS) studies have consistently shown reduction in intracor-
tical inhibition (mediated by intracortical gamma-aminobutyric acid-A
receptors),30 consistent with a hyperexcitable central nervous system. Not
every neurophysiologic study of RLS has been compatible with central
nervous system disinhibition. Brainstem auditory evoked responses and
blink reflex were normal in studies of persons with RLS.11,54,55
Neuroanatomy: bridge to biological pathophysiology of RLS. Clearly,
from the above discussion, there are numerous neuroanatomic regions
that are involved in RLS or in phenomena associated with RLS. What
is not clear is which of these areas is affected primarily by a pathologic
process or derangement that causes RLS, and which of the areas
becomes involved or activated secondarily as a consequence of either
chronic sleep loss or sensorimotor disturbances. Areas of the brain that
serve sensation and movement clearly need to be activated/involved
when RLS symptoms are present. What isn’t known is what causes the
activation of these structures and produces the sensorimotor symptoms
of RLS. In addition to brain regions involved in sensation and
movement, other areas linked to emotion (frontal lobes, cingulate
cortex), arousal (brainstem, cortex), and multimodality (thalamus and
cerebellum) have demonstrated activity when RLS symptoms are
present. Is this simply because it is impossible not to activate such areas
when unpleasant sensations are felt and does activation in these areas
simply represent an uninteresting by-product of discomfort? Or is
there meaningful pathology that occurs primarily in these areas that
drives sensorimotor symptoms of RLS?
Stepping back from neuroanatomy, much investigation has taken
place to identify a pathophysiologic substrate of RLS. Biological
systems that have been studied include the dopaminergic, opioid, iron,
serotonergic, and glutamatergic systems. It is likely that activation and
or abnormalities seen in different brain regions result from a primary
disturbance of some biological system that in turn drives the symptoms
and thus the entity of RLS.
Dopamine function in RLS
It is well known that RLS symptoms can be successfully treated with
medicines having dopamine agonist properties. This fact has driven
much of the work that has looked at the dopamine system and its
relation to RLS. Early on, studies aimed to verify a predominant
Figure 1. Periodic LimbMovements During Sleep Demonstrated By Polysomnography. Periodic limb movements during sleep are displayed as demonstrated
by periodically occurring (every 20–30 seconds) activations of anterior tibialis electromyography. Also noticeable in this schematic are activations of electroencephalography,
in the form of synchronous cortical firing (K-complexes) and acceleration of heart rate as evidenced by shortening of the R-R interval on electrocardiography.
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notion that there was brain dopamine deficiency, but studies have not
supported this notion. The first cerebrospinal fluid studies of RLS
demonstrated normal dopaminergic and serotonergic metabolites in
untreated persons with RLS compared with controls.56 A later study
by a separate group showed that persons with RLS have higher levels
of 3-ortho-methyldopa, a dopamine metabolite, that correlates with
RLS symptom severity.57
Brain imaging studies of the dopaminergic system in RLS have been
contradictory. Early positron emission tomography (PET) studies in
untreated RLS patients showed lower dopamine (D2) binding potential
in the striatum.36,58 Similarly, lower striatal dopamine (D2) binding
potential was found in a later PET study of RLS. This study did not
find a difference in dopamine receptor affinity or density, and thus the
finding of decreased dopamine binding potential was interpreted to
suggest an increase in synaptic dopamine.59 Two single photon
emission computed tomography studies yielded opposite results,
showing both increased and decreased binding potential of dopamine
transporter in the striatum of RLS subjects.26,60 Another photon
emission computed tomography study found normal dopamine-2
receptor binding in the striatum of RLS patients.23,25 A post-mortem
study conducted by Connor et al.37 is consistent with overactivity of
the dopamine system in the brain. Brains of patients with RLS
demonstrated a decrease in dopamine-2 receptor levels in the putamen
and an increase in tyrosine hydroxylase in the substantia nigra. The
sum of these metabolic, imaging, and pathologic studies suggests that
in RLS there is a relative increase in striatal dopamine, but this
supposition needs greater support.
Further insight into the involvement of dopamine comes from
considering the phenomenon of augmentation, which is characterized
by paradoxical worsening of RLS symptoms in the setting of
dopaminergic treatment.61 Increased striatal dopamine stimulation
likely produces a post-synaptic downregulation at the receptor level,
perhaps enough to maintain an equilibrated dopaminergic state during
the day. At night, when circadian influences result in a relative
dopamine deficit with low dopamine receptor levels, RLS symptoms
may emerge. Treatment with dopaminergic medication at night can
temporarily restore balance; however, adding dopamine to a
dopamine excess state invariably worsens the situation, and augmenta-
tion may result. For this reason, the dopaminergic medications for
many RLS practitioners have fallen out of favor, for the alpha-2-delta
ligands (gabapentin and pregabalin).
Iron deficiency
Although pharmacological treatment data support involvement of
the dopaminergic system in RLS pathophysiology, recent evidence
shows that iron depletion is an additional contributing factor. Several
studies have shown a relation between low serum ferritin and
symptoms of RLS62,63; furthermore, RLS improves with the admin-
istration of oral or intravenous iron.64,65 In addition, cerebrospinal
fluid (CSF) ferritin levels are 65% lower and CSF transferrin levels are
three times higher in RLS patients than age-matched controls.66
Low brain iron has been demonstrated by both imaging and
neuropathological studies of the RLS brain. Allen et al.12 evaluated the
iron concentration or ‘‘iron index’’ in 10 brain regions with MRI in
early and late onset RLS patients and controls. The mean iron index
for the substantia nigra was significantly lower for early-onset but not
for late-onset RLS patients compared with controls. Neuropathology
in RLS has demonstrated a decrease in ferritin and increase in
transferrin in neuromelanin containing cells of the substantia nigra in
RLS,15 complementing prior CSF findings in RLS patients.66
One inconsistent finding of this autopsy study was a relative
decreased staining intensity for transferrin receptors in RLS brains.
Normally, an iron-deficient cell should have an increase in transferrin
receptors. In addition, there were differences noted in the expression of
transporter proteins in neuromelanin cells. The expression of the
divalent metal transporter protein 1 was found rarely in neuromelanin
cells in RLS brains compared with normal brains. Divalent metal
transporter protein 1 helps remove iron from endosomes, making iron
available in the intracellular iron pool.67 Another iron transport
protein, metal transporter 1, involved in cellular iron efflux, was
minimally detected in neuromelanin cells of RLS brains.68 Thus, the
lack of appropriate increase in transferrin receptor expression in
response to less iron; and a relative decrease in iron transporter protein
concentration in RLS suggests that there is a malfunction of central
iron acquisition and transport in RLS patients.
Opioid system
The endogenous opioid system may also be involved in RLS
pathophysiology,69 again suggested by the often exquisite therapeutic
response of RLS to opioid medications.70,71 There is some evidence of
endogenous opioid deficiency in RLS. A post-mortem study of RLS
patients showed that b-endorphin and met-enkephalin endogenous
opioids were significantly decreased in the thalamus of RLS compared
with control subjects.41 In an animal model of RLS, m-opioid receptor
knockout mice showed hyperactivity and iron deficiency.72
There are important interactions among the iron, dopamine, and
opioid systems, in general, and in how they may relate to RLS. Iron is
a necessary cofactor in the formation of L-dopa from L-tyrosine
through action of tyrosine hydroxylase. In an in vitro model, Sun
et al.73 demonstrated decreased survival of dopaminergic cells exposed
to iron deficiency, but that opioid receptor agonism protected
dopaminergic cells from cell death.
Glutamatergic system
It is well known that there are sleep–wake and arousal abnormalities
associated with RLS, yet it is difficult to attribute these abnormalities to
dopamine or iron. Abnormal sensations and heightened arousal are
important features of RLS, and both may invoke the thalamus, an area
that shows increased activity when RLS symptoms are present. Using
this thinking as the impetus, a recent study examined the thalamus in
RLS subjects by magnetic resonance spectroscopy, focusing on the
glutamatergic system. Glutamatergic activity was increased in the
thalamus of RLS patients compared with controls, and intriguingly total
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activity correlated with time spent awake after sleep onset, but not with
PLMS frequency.40 This study suggests that thalamic glutamatergic
hyperactivity underlies heightened arousal but not PLMS in RLS.
Hyperpolarization of thalamocortical neurons is responsible for sleep
spindle generation and decreasing cortical sensory inputs.74 Increased
thalamocortical excitation can cause increased wakefulness and
decreased non-rapid eye movement stage 2 sleep (seen in RLS).
Pertinent to this pathophysiology is the therapeutic response of RLS to
a-2-d ligands, gabapentin, pregabalin, and gabapentin enacarbil, which
decrease glutamate release, lessen RLS symptoms, and improve sleep
continuity.75–77
Serotonergic system
Medicines that increase serotonin bioavailability (antidepressants)
have been associated with increased risk or aggravation of RLS and
PLMS.78,79 In a large epidemiological study, Ohayon et al.80 showed
that use of serotonin reuptake inhibitor antidepressants was associated
with a threefold increased risk of RLS. Antidepressants, serotonin
reuptake inhibitors, and venlafaxine have been similarly shown to be
associated with increased risk (about fivefold) of having PLMS in a
large cohort of patients.81 The pathophysiologic role of serotonin in
RLS has been scarcely studied. One study employing magnetic
resonance spectroscopy found similar availability of serotonin
transporter protein in pons and medulla in RLS and control subjects;
but RLS severity did increase with decreased transporter availability.
This finding suggests that dysregulation of serotonergic neurotransmis-
sion may provoke or exacerbate RLS, implicating yet another
neurotransmitter system in RLS pathophysiology.38
Hypoxia
There are clues that hypoxia, both in the periphery and brain, may
play a role in RLS. In one study, patients with RLS had significantly
lower partial oxygen pressure than controls in the legs but not chest
when both groups were subjected to prolonged immobilization.82
Furthermore, increasing severity of RLS correlated with higher chest-
to-foot oxygen gradients (r50.692, p,0.01). Finally, treatment with a
dopamine agonist improved peripheral hypoxia toward levels observed
in controls. Hypoxia-inducible factor-1a (HIF-1a) is a subunit of the
transcription factor HIF-1 that regulates the cellular and develop-
mental response to hypoxia.83 Immunohistochemical analyses of
substantia nigra tissue from six RLS and six control patients showed
HIF-1a was increased in RLS subjects.
Interestingly, hypoxia may be linked to the dopamine and iron
systems. Connor et al.37 showed that tyrosine hydroxylase levels are
elevated in post-mortem brains in RLS patients. Tyrosine hydroxylase
is the rate-limiting enzyme in dopamine synthesis, and requires iron for
its activity. Elevation in tyrosine hydroxylase activity in RLS occurs
despite a state of iron deficiency. This could be explained by the
presence of hypoxia in RLS, as the tyrosine hydroxylase gene
promoter region contains a hypoxia-responsive element that causes
increased gene expression of tyrosine hydroxylase in the presence of
hypoxia.84
Peripheral and autonomic nervous systems and consideration of
PLMS
Although it is fairly well accepted that peripheral neuropathy may
be the de novo cause of or exacerbate RLS,85 it is controversial
whether or not there is subclinical small fiber neuropathy in patients
with primary RLS who have normal neurological examinations and
normal conduction studies. Some studies have indicated that patients
with primary RLS have sensory abnormalities with quantitative
sensory testing, including increased pin prick sensitivity.85–88 However,
other examinations of small neuronal fibers in idiopathic RLS, using
quantitative sudomotor and skin sympathetic testing, demonstrated
normal sweating and intact A-delta and C-fibers, arguing against small
fiber neuropathy.88–90 Biopsy has also demonstrated a high concurrence
of small fiber neuropathy, especially in late-onset RLS in approximately
one-third of patients.91 However, this still leaves two-thirds of RLS
patients that cannot be accounted for by subclinical small fiber
neuropathy. Measuring vascular response to exercise and sympathomi-
metic medication, patients with RLS demonstrate a depressed arterial
baroreflex response and have greater peripheral vascular resistance,
potentially reflecting heightened sympathetic outflow.92
Additionally, increased spinal cord excitability in the form of
reduced threshold and increased spatial spread of the flexor reflex has
been demonstrated in RLS patients. One study showed multiple late
responses in the spinal flexor response with long duration in RLS
patients, again suggesting spinal hyperexcitability.93
PLMS occur in up to 90% of persons with RLS.6 Recent studies
suggest that the autonomic nervous system is involved in PLMS
pathogenesis. Stereotypically, PLMS co-occur with discrete increases
in blood pressure measuring about 22 mmHg.94,95 The magnitude of
pressure elevations is greatest when there is accompanying arousal
from sleep. The co-occurrence of this sympathetic hyperactivity and
PLMS suggests activation of the thoracolumbar spinal cord, where
sympathetic preganglionic neurons arise. RLS patients have abnormal
cardiovascular autonomic function with a tendency toward hyperten-
sion, reduced amplitude of both sympathetic and parasympathetic
responses during the tilt test, as well as blunted parasympathetic drive
to blood pressure changes.96 These findings are in agreement with
epidemiological studies that have found a tendency toward hyperten-
sion and enhanced cardiovascular risk in RLS.97
Clarification of RLS pathophysiology through genetics
RLS is highly familial with estimates of heritability between 54%
and 83% by twin studies.98,99 Positive genetic findings in RLS have
come through familial linkage and genome-wide association studies.
Genetic linkage studies have found gene regions that are associated
with RLS, loci RLS1 through RLS5, but have not implicated specific
genes.100,101 On the other hand, genome-wide association studies
have identified specific genes that are associated with RLS across
different populations and study groups. Genes that are likely associated
with the presence of RLS include BTBD9, MEIS1, PTPRD, MAP2K5,
SKOR1, and TOX3.102–106 Within these genes, several common single
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nucleotide polymorphisms have demonstrated significant association
with the phenotype of RLS (Table 2). At this point, how and if these
different genetic variants result in an RLS phenotype is not known. But
animal models, for BTBD9 and MEIS1, which are currently underway,
are beginning to disentangle the mechanisms by which these genes may
be associated with RLS.107,108 We will further comment on the genetic
associations of RLS and BTBD9 and MEIS1. It is important to note, that
some of these studies showed association more so for PLMS than for
RLS.102,106 There are perhaps competing factors to consider. PLMS
occur in the majority of persons with RLS6; however, they also occur
commonly in persons without RLS, including those with sleep apnea,
narcolepsy, and in normal elderly.109–111 Although, there is non-
specificity as to what group of persons has PLMS, it is a phenomenon
that is objectively measured rather than subjectively considered, which
may decrease false positivity that so often occurs in RLS diagnosis.112
BTBD9
BTBD9 is expressed widely in the central nervous system and is
involved in synaptic plasticity and learning. Early knockout studies
showed that mice and flies lacking BTBD9 expression display an RLS-
like phenotype of sleep fragmentation and motor restlessness, which,
like RLS, is reversed with the administration of a dopamine
agonist.107,108 Also consistent with RLS, flies lacking BTBD9 have a
marked reduction in whole brain dopamine compared with wild-type
flies. This same group demonstrated in a human embryonic kidney cell
line that overexpression of BTBD9 results in increased ferritin.107
These findings are consistent with one or more features of RLS. Much
more is likely to be learned about BTBD9, as there is active
investigation of this gene and the consequences of its perturbation.
MEIS1
MEIS1 is a homeobox gene, thought to be important in normal limb
formation and motor neuron connectivity. Also MEIS1-expressing cells
appear to be involved in formation of nigrostriatal projection
neurons.117 The presence of the MEIS1 risk allele is associated with
a nearly 50% increased odds of having RLS.103 And persons with this
MEIS1 risk allele have decreased MEIS1 mRNA and protein in
lymphoblastoid cell lines.118 MEIS1 seems to have an association with
the iron system and perhaps via this pathway affects RLS. In a
Caenorhabditis elegans model, RNA knockdown of MEIS1 increased
expression of ferritin.118 A recent study indicated that the allelic
variations in this gene that are associated with RLS lead to
developmental changes in the telencephalon, suggesting that RLS
could be a neurodevelopmental disorder.119 There is much that still
needs clarification about the role of MEIS1 in RLS.
Summary and conclusion
Through neuroimaging, neurophysiologic, and neuropathologic
analyses many different regions of the central nervous system have
been studied in attempts to clarify the pathogenesis of RLS. These
areas include those that subserve sensation and movement including
the pre- and post-central cortices, thalamus, and striatum, and these
may be primarily affected by pathological changes in one or more
biological systems. Through sensorimotor discomfort and sleep loss,
additional neuroanatomic structures, such as the cingulate and other
Table 2. Genes Implicated in RLS and PLMS: Cohort, Location, and Function
Gene Chromosome Function SNP Cohort















PTPRD 9p23-24 Protein tyrosine
phosphatase regulates cell
growth, mitosis
rs4626664, rs1975197 Korea,115 United States116








TOX3 16q12.1 Transcription factor Rs3104767, rs3104788 Germany117
Abbreviations: PLMS, Periodic Limb Movements during Sleep; RLS, Restless Legs Syndrome; SNP, Single Nucleotide Polymorphism.
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cortical areas, the cerebellum, and brainstem arousal areas may
become involved.
Research to clarify the biological underpinnings of RLS has
included studying the role of brain iron and the endogenous opioid,
dopamine, glutamate, and serotonin systems, the first two showing
deficiency and the last three showing increased function. The paradox
that RLS responds to dopaminergic agents despite autopsy evidence
that dopamine is hyperfunctional in RLS remains yet to be resolved37;
however, this may explain to some extent the phenomenon of
augmentation. Findings related to dopamine in RLS have been
inconstant. This paired with the likelihood that increased dopamine
results secondarily from a problem with iron handling or storage argue
against dopamine dysfunction as the primary mechanism in RLS.
On the other hand, the most consistently found biological
abnormality in RLS is a deficiency of brain iron in the substantia
nigra, red nucleus, putamen, caudate, and thalamus.12–15,22 Ferritin in
the blood of RLS patients is commonly low, but iron measures
themselves are often normal in RLS. The sum of these findings
suggests an impairment of iron transport into the brain, and more
specifically into neuromelanin-containing cells of the substantia nigra.
Iron, itself, is an essential cofactor for tyrosine hydroxylase in the
enzymatic conversion of L-tyrosine to L-dopa, the main precursor to
dopamine. Much has been learned about how the iron and dopamine
systems interact through the use of iron-deficient animal models. Iron
deficiency in the rat is associated with increased presynaptic dopamine
and dopamine uptake transporter dysfunction.120,121 These findings
suggest that changes in dopamine are secondary to iron deficiency, but
it remains unclear why iron is deficient in certain brain regions.
The formation of L-dopa is accomplished by the hydroxylation of
L-tyrosine. One oxygen atom is taken from molecular oxygen as it
reacts with ferrous iron to form an additional hydroxyl group of
L-dopa. Hypoxia, by activating HIF-1a, leads to upregulation of
tyrosine hydroxylase and a dopamine transporter.122 Hypoxia in RLS
is suggested by increased muscle microvascularization and increased
vascular endothelial growth factor in muscle of RLS patients.123,124
Furthermore, increased HIF-1a immunoreactivity has been found in
the substantia nigra of RLS patients.83 Although this finding could
have been produced by hypoxia itself, HIF-1a can also be activated
under conditions of iron deficiency.125 So the question remains when
considering the interactions among iron, dopamine, and hypoxia: Are
abnormalities in one of these systems driving changes in the others?
Clearly, there are numerous neuroanatomic regions involved in
RLS. It is still unclear which areas are affected primarily by a
pathologic process that causes RLS, as opposed to affected secondarily
as a consequence of either chronic sleep loss or sensorimotor
disturbances. It is likely that within these differing neuroanatomic
regions, various biological systems are involved in producing the RLS
state, including the dopaminergic, opioid, iron, serotonergic, and
glutamatergic systems.
Both clinicians and basic researchers will be essential in the effort to
determine the underlying causes of RLS. As a common disease, RLS is
likely not homogeneous but rather a spectrum that within it may have
different subtypes. There needs to be research about the onset of RLS,
early versus late, the prominence of certain sensory features such as
pain or crawling, the presence or absence of PLMS, and the co-
occurrence of RLS with depression or hypertension. Studies of
children with RLS will be increasingly important as they will provide
clues when and why iron deficiency takes place. The search for a
biomarker, either genetic, serologic, or in spinal fluid, should continue
fervently. Clinical, animal, genetic, and cellular models should be
included.
At the most basic level of this research, an explanation for what
causes the peculiar symptoms of RLS that are so central to its clinical
identification is still lacking. Yet in consideration of RLS pathophy-
siology, sensorimotor symptoms and an exploration for what causes
the signature, urge to move, are often sidelined. The key to uncovering
the RLS mystery may lie in the correct decoding of symptoms that
drive movement. And it could be that listening to the patient is what
may drive this movement to where it ought to be.
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